Two inhaled pulmonary vasodilators worked similarly in preventing postoperative right ventricular (RV) failure after major cardiac surgery for advanced heart failure, according to a randomized study, ...

Dallas, TX - As new agents are developed for the treatment of primary pulmonary hypertension (PPH), long-term data are now becoming available on the first drug approved for this indication, ...

Epoprostenol (FLOLAN) is an intravenous medication used to treat primary pulmonary hypertension (PPH), a condition characterized by progressive increases in pulmonary artery pressure, leading to right ...

Discover comprehensive details about Epoprostenol, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Contraindicated in people with congestive heart failure, lung swelling and hypersensitivity. Caution should be exercised in patients with history of bleeding problem, heart failure, liver or kidney, ...

LOS ANGELES -- For surgeons already split on their preference of inhaled pulmonary vasodilator to prevent postoperative right ventricular (RV) failure, a shifting market is not helping decision-making ...

The advent of epoprostenol for the treatment of pulmonary arterial hypertension has dramatically improved survival in adults; however, data on the use of this agent in pediatric cases are lacking. In ...

SOUTH SAN FRANCISCO, Calif., Aug. 25 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the brand name VELETRI® for the ...

DALLAS, Aug. 27 – Long-term use of a vasodilator drug can significantly increase survival and improve quality of life in patients with primary pulmonary hypertension (PPH), according to the first ...

The FDA has approved the brand name for commercially available Veletri (epoprostenol for injection) for pulmonary arterial hypertension (PAH). “Veletri is a proven therapy for the treatment of PAH ...

Actelion Pharmaceuticals Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application for Second Generation VELETRI(R) (epoprostenol) for Injection SOUTH SAN FRANCISCO, CA ...